Ipreimma Yervoy combination may “potentially cure” BMS

2022-06-03 0 By

The combination of Yervoy and Opdivo may provide survival benefits for asymptomatic melanoma patients with BMS, although more efforts are needed to include this patient population in trials.Patients with asymptomatic melanoma with brain metastases treated with Yervoy (ipilimumab) and Opdivo (nivolumab) were still responding to treatment after three years, with improved survival, the study showed.The CheckMate 204 findings, published in The Lancet Oncology, also confirm that symptomatic melanoma patients with BMS remain a hard-to-treat population, although some patients did achieve long-term results with the Yervoy- Opdivo combination of Ipreimma.”This study adds to the evidence that this is an effective way to improve survival.”Hussein A. Tawbi, PhD, professor of melanoma medical Oncology, Associate director of the Division of Melanoma Medical Oncology, and clinical co-director of Brain metastases at the University of Texas MD Anderson Cancer Center in Houston, told CURE®.”It will help [medical oncologists] tell their patients that it’s not just about inducing a response.It’s a way to help you heal, and it’s important for radiation oncologists, neurosurgeons and other healthcare providers to realize that sometimes immunotherapy can be a very good option for these patients.”Tawbi added that radiation or surgery are no longer the only options to help heal patients.Although they are important methods, most of the time they are used for palliative rather than therapeutic purposes.”It’s a huge advance to be able to say that we have treated patients with melanoma and we have the potential to cure them even if they have brain metastases,” Tawbi said.Evaluating treatment in asymptomatic versus symptomatic Patients In the phase II study, researchers analyzed data from 119 patients with melanoma with brain metastases, 101 asymptomatic and 18 symptomatic.Patients with symptoms can be treated with low-dose dexamethasone.Both groups were treated with four doses of Yervoy Ganabumab Opdivo every three weeks, followed by Opdivo every two weeks for up to two years until toxicity or disease progression.Several areas of focus in this study include intracranial clinical benefit rate (defined as complete response, partial response, or stable disease lasting at least six months), intracranial progression-free survival (the time patients survive without worsening) and overall survival (the time patients with cancer are still alive).The mean follow-up time was 34.3 months for asymptomatic patients and 7.5 months for symptomatic patients.Intracranial clinical benefit was observed in 57.4% of asymptomatic patients and 16.7% of symptomatic patients.In addition, 53.5% of asymptomatic patients and 16.7% of symptomatic patients had a measurable response to treatment.Complete intracranial response to treatment was observed in 33% of asymptomatic patients and 17% of symptomatic patients.54.1% of asymptomatic patients and 18.9% of patients experienced 36-month intracranial progression-free survival.Overall survival was also higher in asymptomatic patients compared with symptomatic patients (71.9% vs 36.6%).Among the 15 percent of asymptomatic patients treated with Ipilimma Yervoy ganavumab Opdivo, the most common severe or life-threatening side effect was elevated alanine aminotransferase and aspartate aminotransferase, both of which indicate possible liver disease.More than one symptomatic patient did not experience serious treatment-related side effects or life-threatening side effects.The most common treatment-related side effects were diarrhea, colitis, elevated alanine aminotransferase, and pituitary inflammation.A treatment-related death occurred in an asymptomatic patient associated with myocarditis.Despite these findings, especially in asymptomatic patients, more research is needed in this area, Tawbi said.”55% of the responses were really good, but I was greedy;I want all my patents to respond, AND I want them all to survive.””I’m afraid the other 45 percent didn’t respond.I want to create and come up with new approaches for them, new therapies that can help us increase response rates.”Tawbi says there is also a need to focus on symptomatic patients who need steroids, which has been present in cancer clinics.”I knew immunotherapy wasn’t going to work that well for them,” he said.”We need to find ways to help these patients through surgery, radiation, targeted therapies or new approaches that may help us improve outcomes for these patients.”In the study excluded patients with brain metastases Although Tawbi and his team is aware of the requirements are not met, he points out that, unfortunately, many studies have ruled out in patients with brain metastasis, for several reasons: they are usually more serious condition, prognosis is poor, and most drugs designed to not enter the patient’s brain, because of the potential neurotoxic and other side effects.”Because of that, these populations will be excluded, not included in the study, and they will deteriorate very quickly,” Tawbi said. “These drugs don’t work on the brain, so let’s treat them with radiation or surgery.”.”It doesn’t hold water because first of all, we’re starting to see some of these drugs work in the brain, even if they don’t penetrate [the brain]…(Ipreimmayervoy and Opdivo) are relatively large molecules that don’t normally enter the brain, but the immune system does.If you activate the immune system, you definitely get an immune response, and that’s what we saw in the study.”Tawbi and his colleagues recognized the improvements needed to study patients with melanoma with brain metastases.”We need to do better,” he said.”There are so many drugs in the pipeline, melanoma and other cancers are improving across the board, and this population is still on the sidelines.I don’t think that’s acceptable.It is estimated that up to 30% of patients with metastatic solid tumors will eventually develop BMS, and we are working on that.We’re just completely ignoring this group.”Note: the pictures in this article have been authorized by the copyright party: the copyright of this article belongs to the original author, if there is a source error or infringement of your legitimate rights and interests, you can contact us through email, we will promptly deal with.Email address: jpbl@jp.jiupainews.com